In this March 2026 edition of Drugs.com Monthly Update Podcast, learn about the FDA's latest approvals, including Wegovy HD for obesity, Icotyde for plaque psoriasis, Sotyktu for psoriatic arthritis, and Awiqli for type 2 diabetes.

Wegovy HD (semaglutide): A new high-dose option for adults managing obesity, showing significant weight loss in clinical trials.

Icotyde (icotrokinra): The first oral IL-23 blocker approved to treat moderate-to-severe plaque psoriasis, providing a new oral treatment choice.

Sotyktu (deucravacitinib): An oral TYK2 inhibitor now approved for treating active psoriatic arthritis, addressing inflammation with a convenient dosing regimen.

Awiqli (insulin isodec): The first once-weekly basal insulin for adults with type 2 diabetes.

Chapters:

• (00:21) - Intro
• (01:00) - Wegovy HD
• (02:10) - Icotyde
• (03:12) - Sotyktu
• (03:53) - Awiqli
• (04:32) - Outro

• X, Facebook, Youtube
• Sign up to our newsletters
• Download the app

In this February 2026 edition of Drugs.com Monthly Update Podcast, learn about new options in weight management, type 2 diabetes, and lung cancer. Discover Eli Lilly's Zepbound KwikPen for simplified dosing in obesity management, the upcoming launch of the oral Ozempic pill for diabetes by Novo Nordisk, IBSA Pharma’s oral film formulation of sildenafil for erectile dysfunction called Vybrique, and the monthly Rybrevant Faspro injection for advanced NSCLC.

• Zepbound KwikPen (tirzepatide): A new multidose Zepbound pen supplying 4 fixed weekly doses in one pen
• Ozempic pill (semaglutide): Discover the upcoming once-daily oral option for adults with type 2 diabetes to manage blood sugar and cardiovascular risks.
• Rybrevant Faspro (amivantamab and hyaluronidase-lpuj): Explore the benefits of a simplified, monthly injectable regimen for EGFR-mutated NSCLC.
• Dupixent (dupilumab): The first approved therapy for allergic fungal rhinosinusitis, reducing the need for systemic steroids.
• Vybrique (sildenafil): A new oral film formulation of sildenafil for erectile dysfunction.
• Calquence + Venetoclax (acalabrutinib combination): This new all-oral regimen provides a targeted therapy for CLL, improving patient outcomes with a non-chemo approach.

Chapters:

• (00:00) - Intro
• (00:20) - Overview

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

In our latest episode, we cover the latest approval of Darzalex Faspro for multiple myeloma, age-related near vision loss, and a rare genetic disorder affecting children. We also discuss an extension to the use of Nexplanon, a long-acting birth control, and a simpler transition for those moving from injected to inhaled insulin.

• Darzalex Faspro (daratumumab and hyaluronidase-fihj) a new approval for use in combination with standard treatments for adults with newly diagnosed multiple myeloma.
• Yuvezzi (carbachol and brimonidine tartrate), a novel combination eye drop for presbyopia.
• Zycubo (copper histidinate), the first treatment for Menkes disease in children.
• Nexplanon (etonogestrel), a birth control implant with an extension of use for up to five years.
• Afrezza (insulin human), an inhaled insulin, with updated dosing guidance.

Chapters

• (00:00) - Intro
• (00:21) - Overview
• (00:47) - Darzalex
• (02:13) - Yuvezzi
• (03:06) - Zycubo
• (03:50) - Nexplanon
• (04:35) - Afrezza
• (05:09) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app